Patient demographics and baseline characteristics
| . | BV+DTIC (n = 22) . | BV+bendamustine (n = 20) . |
|---|---|---|
| Median age, y (min, max) | 69 (62, 88) | 75 (63, 86) |
| Male | 16 (73) | 10 (50) |
| Race | ||
| Black or African American | 3 (14) | 0 |
| White | 19 (86) | 20 (100) |
| ECOG performance status | ||
| 0/1 | 15 (68) | 16 (80) |
| 2/3 | 7 (32) | 4 (20) |
| Patients ineligible for conventional chemotherapy | 19 (86) | 17 (85) |
| Histologic subtype of Hodgkin HL | ||
| Nodular sclerosis | 9 (41) | 10 (50) |
| Mixed cellularity | 9 (41) | 4 (20) |
| Lymphocyte-rich classical HL | 0 | 1 (5) |
| Lymphocyte-depleted classical HL | 1 (5) | 1 (5) |
| Classical HL not otherwise specified | 3 (14) | 4 (20) |
| Disease stage at diagnosis | ||
| I/II | 6 (27) | 5 (25) |
| III/IV | 16 (72) | 15 (75) |
| Median percent CD30 expression (min, max) | 95 (4, 100) | 95 (40, 100) |
| Baseline B symptoms | ||
| Fever | 2 (9) | 2 (10) |
| Night sweats | 5 (23) | 6 (30) |
| Weight loss >10% | 3 (14) | 5 (25) |
| Bulky disease | 2 (9) | 1 (5) |
| Extranodal involvement | 9 (41) | 8 (40) |
| Baseline renal function | ||
| Unimpaired (CrCl >80 mL/min) | 11 (50) | 6 (30) |
| Mild (CrCl >50 to ≤80 mL/min) | 6 (27) | 10 (50) |
| Moderate (CrCl ≥30 to ≤50 mL/min) | 3 (14) | 4 (20) |
| Severe (CrCl <30 mL/min) | 2 (9) | 0 |
| Median percent cardiac ejection fraction* (min, max) | 60 (25, 72) | 60 (45, 70) |
| . | BV+DTIC (n = 22) . | BV+bendamustine (n = 20) . |
|---|---|---|
| Median age, y (min, max) | 69 (62, 88) | 75 (63, 86) |
| Male | 16 (73) | 10 (50) |
| Race | ||
| Black or African American | 3 (14) | 0 |
| White | 19 (86) | 20 (100) |
| ECOG performance status | ||
| 0/1 | 15 (68) | 16 (80) |
| 2/3 | 7 (32) | 4 (20) |
| Patients ineligible for conventional chemotherapy | 19 (86) | 17 (85) |
| Histologic subtype of Hodgkin HL | ||
| Nodular sclerosis | 9 (41) | 10 (50) |
| Mixed cellularity | 9 (41) | 4 (20) |
| Lymphocyte-rich classical HL | 0 | 1 (5) |
| Lymphocyte-depleted classical HL | 1 (5) | 1 (5) |
| Classical HL not otherwise specified | 3 (14) | 4 (20) |
| Disease stage at diagnosis | ||
| I/II | 6 (27) | 5 (25) |
| III/IV | 16 (72) | 15 (75) |
| Median percent CD30 expression (min, max) | 95 (4, 100) | 95 (40, 100) |
| Baseline B symptoms | ||
| Fever | 2 (9) | 2 (10) |
| Night sweats | 5 (23) | 6 (30) |
| Weight loss >10% | 3 (14) | 5 (25) |
| Bulky disease | 2 (9) | 1 (5) |
| Extranodal involvement | 9 (41) | 8 (40) |
| Baseline renal function | ||
| Unimpaired (CrCl >80 mL/min) | 11 (50) | 6 (30) |
| Mild (CrCl >50 to ≤80 mL/min) | 6 (27) | 10 (50) |
| Moderate (CrCl ≥30 to ≤50 mL/min) | 3 (14) | 4 (20) |
| Severe (CrCl <30 mL/min) | 2 (9) | 0 |
| Median percent cardiac ejection fraction* (min, max) | 60 (25, 72) | 60 (45, 70) |
Data are presented as n (%) of patients unless otherwise specified.
CrCl, creatinine clearance.
By echocardiogram (17 patients in the BV plus DTIC arm and 19 patients in BV plus bendamustine arm).